Fuan Pharmaceutical (Group) Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Lu Wang
Chief executive officer
CN¥776.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.1yrs |
| CEO ownership | n/a |
| Management average tenure | 13.7yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Shares Fly 36% But Investors Aren't Buying For Growth
Oct 08
There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings
Aug 23Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?
Jun 07Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit
May 02Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price
Apr 03CEO
Lu Wang (40 yo)
3.1yrs
Tenure
CN¥776,200
Compensation
Mr. Lu Wang is Vice Chairman and General manager of Fuan Pharmaceutical (Group) Co., Ltd. from December 10, 2021.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | no data | CN¥776.20k | no data | |
| Deputy GM | 15.3yrs | CN¥608.20k | 0.011% CN¥ 531.7k | |
| Deputy GM & Director | 12.1yrs | CN¥698.70k | 0.74% CN¥ 36.9m | |
| Deputy General Manager | 3.1yrs | CN¥608.00k | 0.000080% CN¥ 4.0k | |
| Secretary of the Board of Directors & Director | 15.3yrs | CN¥607.50k | 0.024% CN¥ 1.2m | |
| Deputy General Manager | no data | CN¥608.20k | 0.023% CN¥ 1.2m | |
| Deputy General Manager | 15.3yrs | CN¥615.80k | 0.016% CN¥ 778.5k | |
| Deputy General Manager | 4.4yrs | CN¥608.00k | 0.025% CN¥ 1.2m |
13.7yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 300194's management team is seasoned and experienced (13.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 3.1yrs | CN¥776.20k | no data | |
| Deputy GM | 15.3yrs | CN¥608.20k | 0.011% CN¥ 531.7k | |
| Deputy GM & Director | 12.1yrs | CN¥698.70k | 0.74% CN¥ 36.9m | |
| Secretary of the Board of Directors & Director | 15.3yrs | CN¥607.50k | 0.024% CN¥ 1.2m | |
| Chairman | 15.3yrs | CN¥919.80k | 24% CN¥ 1.2b | |
| Independent Director | less than a year | no data | no data | |
| Director | 6.6yrs | CN¥631.50k | no data | |
| Independent Director | 6.1yrs | CN¥60.00k | no data | |
| Independent Director | 6.1yrs | CN¥60.00k | no data | |
| Independent Director | 3.1yrs | CN¥60.00k | no data | |
| Non-Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
6.1yrs
Average Tenure
53yo
Average Age
Experienced Board: 300194's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 04:12 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fuan Pharmaceutical (Group) Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Everbright Securities Co. Ltd. |
| Guang Wang | Guoyuan Securities Co., Ltd. |
| Yi Yao | Huatai Research |